Feb 27 (Reuters) - Shares in India's Jubilant Life Sciences
Ltd fell as much as 6.9 percent on Wednesday after
U.S. health regulators issued a warning letter to the company,
citing "significant violations" of manufacturing standards at
its facility in Canada.
The U.S. Food and Drug Administration may hold drug
approvals until Jubilant HollisterStier General Partnership
takes necessary corrective steps, Jubilant said in a statement.
Other bigger Indian companies such as Dr. Reddy's
Laboratories Ltd, Ranbaxy Laboratories LTd,
Sun Pharmaceutical Industries Ltd and Aurobindo Pharma
have all received regulatory warning letters on
compliance over the last four years.
The company said its on-going manufacturing, distribution
and sale of products would not be affected by the warning
letter, and it plans to respond to the drug regulator on or
before March 15.
Shares in Jubilant Life Sciences, which has a market value
of about $548.5 million, fell 4.25 percent to 178 rupees. They
earlier touched a low of 173 rupees. The broader market
was up 0.67 percent.
(Reporting by Kaustubh Kulkarni in Mumbai; Editing by Anand